These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 4363816)

  • 41. The mean duration of motor unit action potentials in patients with myasthenia gravis.
    Oosterhuis HJ; Hootsmans WJ; Veenhuyzen HB; van Zadelhoff I
    Electroencephalogr Clin Neurophysiol; 1972 Jun; 32(6):697-700. PubMed ID: 4121519
    [No Abstract]   [Full Text] [Related]  

  • 42. Affinity of myasthenia drugs to acetylcholinesterase and acetylcholine receptor.
    Seifert SA; Eldefrawi ME
    Biochem Med; 1974 Jul; 10(3):258-65. PubMed ID: 4835406
    [No Abstract]   [Full Text] [Related]  

  • 43. Facilitation of neuromuscular transmission by anticholinesterase drugs.
    BLABER LC
    Br J Pharmacol Chemother; 1963 Feb; 20(1):63-73. PubMed ID: 13971349
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of prostigmin on the basal electromyogram in myasthenia.
    Wochnik-Dyjas D; Niewiadomska M
    Pol Med J; 1970; 9(4):932-8. PubMed ID: 4320112
    [No Abstract]   [Full Text] [Related]  

  • 45. Effects of ethyl alcohol on excitability and on neuromuscular transmission in frog skeletal muscle.
    Inoue F; Frank GB
    Br J Pharmacol Chemother; 1967 May; 30(1):186-93. PubMed ID: 6039972
    [No Abstract]   [Full Text] [Related]  

  • 46. Presentation of myasthenia gravis mimicking blepharospasm.
    Roberts ME; Steiger MJ; Hart IK
    Neurology; 2002 Jan; 58(1):150-1. PubMed ID: 11781428
    [No Abstract]   [Full Text] [Related]  

  • 47. Twitch depression and train-of-four ratio after antagonism of pancuronium with edrophonium, neostigmine, or pyridostigmine.
    Donati F; Ferguson A; Bevan DR
    Anesth Analg; 1983 Mar; 62(3):314-6. PubMed ID: 6299135
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A cause of reversible dysphagia: an unusual presentation of myasthenia gravis.
    Brostoff JM; Dahdaleh D; Birns J
    Eur J Intern Med; 2008 Jan; 19(1):70. PubMed ID: 18206608
    [No Abstract]   [Full Text] [Related]  

  • 49. Treatment of myasthenia. II.
    Br Med J; 1971 Apr; 2(5755):213-4. PubMed ID: 5575956
    [No Abstract]   [Full Text] [Related]  

  • 50. Effect of glucocorticoids on plasma cholinesterase in the rat.
    Bradamante V; Kunec-Vajić E
    Biomed Biochim Acta; 1987; 46(6):439-43. PubMed ID: 3675562
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of dopamine and other catecholamines on neuromuscular transmission.
    Blum K
    Arch Int Pharmacodyn Ther; 1969 Oct; 181(2):297-306. PubMed ID: 4326551
    [No Abstract]   [Full Text] [Related]  

  • 52. Myasthenia gravis: an unusual cause of diplopia in polymyalgia rheumatica.
    Fernández-Castro M; Andreu JL; Muñoz P; Ornilla E
    Clin Exp Rheumatol; 2004; 22(4):505. PubMed ID: 15301257
    [No Abstract]   [Full Text] [Related]  

  • 53. Diagnostic challenge: Myasthenia gravis in the emergency department.
    Abbott SA
    J Am Acad Nurse Pract; 2010 Sep; 22(9):468-73. PubMed ID: 20854638
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stabilising action of anti-inflammatory steroids on lysosomes.
    Symons AM; Lewis DA; Ancill RJ
    Biochem Pharmacol; 1969 Oct; 18(10):2581-2. PubMed ID: 5403994
    [No Abstract]   [Full Text] [Related]  

  • 55. The effect of dithiothreitol on anticholinesterase induced antidromic firing and twitch potentiation [proceedings].
    Clark AL; Hobbiger F; Terrar DA
    Br J Pharmacol; 1979 Nov; 67(3):481P-482P. PubMed ID: 497592
    [No Abstract]   [Full Text] [Related]  

  • 56. Structure-activity relationship of reversible cholinesterase inhibitors: activation, channel blockade and stereospecificity of the nicotinic acetylcholine receptor-ion channel complex.
    Albuquerque EX; Aracava Y; Cintra WM; Brossi A; Schönenberger B; Deshpande SS
    Braz J Med Biol Res; 1988; 21(6):1173-96. PubMed ID: 3074841
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A re-evaluation of the decamethonium test for myasthenia gravis.
    Meadows JC; Ross-Russell RW; Wise RP
    Acta Neurol Scand; 1974; 50(2):248-56. PubMed ID: 4835620
    [No Abstract]   [Full Text] [Related]  

  • 58. [Pseudoparalytic myasthenia gravis. Diagnostic and therapeutic aspects in 60 separate cases].
    Mumenthaler M; Lütschg J
    Schweiz Arch Neurol Neurochir Psychiatr; 1976; 118(1):23-56. PubMed ID: 981976
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of the potencies of edrophonium, neostigmine and eserine with a new anticholinesterase drug RX 67668 on human tissues.
    Turner P; Variava DM
    Br J Pharmacol; 1973 Mar; 47(3):678P. PubMed ID: 4730883
    [No Abstract]   [Full Text] [Related]  

  • 60. Corticotropin therapy in patients with myasthenia gravis. Electrophysiologic, pharmacologic studies.
    Namba T
    Arch Neurol; 1972 Feb; 26(2):144-50. PubMed ID: 4332732
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.